CIK 0001822462 · Non-accelerated filer<br>Smaller reporting company
Foghorn Therapeutics Inc.
Sign in to watch- Ticker
- FHTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-586-3100
- Business address
- 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE, MA, 02139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-08-20 | GOTTSCHALK ADRIAN Chief Executive Officer | Option exercise | +23,000 | $0.54 | $12K | 446,479 |
| 2021-08-20 | GOTTSCHALK ADRIAN Chief Executive Officer | Option exercise · Stock Options (Right to buy) | −23,000 | 458,925 | ||
| 2021-08-09 | Reine Allan Chief Financial Officer | Option exercise | +26,892 | $3.72 | $100K | 53,784 |
| 2021-08-09 | Reine Allan Chief Financial Officer | Option exercise · Stock Options (Right to buy) | +26,892 | 257,512 | ||
| 2021-07-13 | Mendelsohn Michael Director | Grant or award · Stock Option (right to buy) | +12,530 | 12,530 | ||
| 2021-07-13 | Koppel Adam Director | Grant or award · Stock Option (right to buy) | +12,530 | 12,530 | ||
| 2021-07-13 | KADOCH CIGALL Director | Grant or award · Stock Option (right to buy) | +12,530 | 12,530 | ||
| 2021-07-13 | GILL SIMBA Director | Grant or award · Stock Option (right to buy) | +12,530 | 12,530 | ||
| 2021-07-13 | Cole Douglas G. Director | Grant or award · Stock Option (right to buy) | +12,530 | 12,530 | ||
| 2021-07-13 | Biller Scott Director | Grant or award · Stock Option (right to buy) | +12,530 | 12,530 | ||
| 2021-06-23 | SMITH IAN F Director | Grant or award · Stock Options (Right to buy) | +12,530 | 12,530 | ||
| 2021-04-27 | SMITH IAN F Director | Grant or award · Stock Options (Right to buy) | +25,060 | $11.50 | $288K | 25,060 |
| 2021-01-28 | DECICCO CARL Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2021-01-28 | Agresta Samuel Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2021-01-28 | Reine Allan Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2021-01-28 | GOTTSCHALK ADRIAN See Remarks | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2020-11-17 | LaCascia Michael Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +162,162 | 162,162 | ||
| 2020-10-27 | DECICCO CARL Chief Scientific Officer | Purchase | +5,500 | $16.00 | $88K | 258,397 |
| 2020-10-27 | GOTTSCHALK ADRIAN See Remarks | Conversion | +25,225 | 25,225 | ||
| 2020-10-27 | GOTTSCHALK ADRIAN See Remarks | Conversion · Series A-2 Convertible Preferred Stock | −18,018 | 0 |
Page 8 of 9 · 177 trades